ProKidney (PROK) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed ProKidney (PROK) over the past year, gaining 91.1% versus a loss of 47.0%. Over five years, SLN leads with a -55.0% price change compared with -84.1% for PROK. ProKidney is the larger company by market cap ($654.7 million vs $586.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | SLN |
|---|---|---|
| Share price | $1.64 | $9.44 |
| Market cap | $654.66M | $586.73M |
| 1-day change | +4.44% | -3.87% |
| YTD return | -29.91% | +61.51% |
| 1-year return | -46.96% | +91.05% |
| 5-year return | -84.09% | -55.00% |
| EPS (TTM) | $-0.55 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.48 | $17.58 |
| 52-week low | $1.30 | $4.19 |
| Distance from 52-week high | -52.87% | -46.29% |
| Analyst consensus | none | buy |
| Avg. price target upside | +281.10% | +249.58% |
| Average volume | 1.30M | 1.12M |
| Shares outstanding | 208.93M | 62.15M |
| Employees | 231 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed PROK by 138.0 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
PROK vs SLN FAQ
Which is bigger, ProKidney or Silence Therapeutics Plc American Depository Share?
ProKidney (PROK) is larger, with a market capitalization of $654.66M compared with $586.73M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, PROK or SLN?
SLN returned +91.05% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Silence Therapeutics Plc American Depository Share in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ProKidney and Biotechnology: Pharmaceutical Preparations for Silence Therapeutics Plc American Depository Share.